| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 1.848 | 0 | 6.963 | 6.047 | 8.751 | 0 | 0 | 0 | 0 | 0 |
| Total Income - EUR | 1.856 | 0 | 6.974 | 6.054 | 8.751 | 0 | 0 | 0 | 0 | 0 |
| Total Expenses - EUR | 1.986 | 1.041 | 564 | 1.410 | 3.897 | 186 | 169 | 233 | 1.467 | 0 |
| Gross Profit/Loss - EUR | -131 | -1.041 | 6.410 | 4.644 | 4.853 | -186 | -169 | -233 | -1.467 | 0 |
| Net Profit/Loss - EUR | -186 | -1.041 | 6.201 | 4.462 | 4.591 | -186 | -169 | -233 | -1.467 | 0 |
| Employees | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 1 |
Check the financial reports for the company - Yrma Pharm Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 4 | 372 | 366 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 6.596 | 4.271 | 10.063 | 14.364 | 18.758 | 18.134 | 17.563 | 17.384 | 15.865 | 15.776 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 1.212 | 1.200 | 7.939 | 13.341 | 18.326 | 17.841 | 17.416 | 17.402 | 15.883 | 15.794 |
| Cash | 5.384 | 3.071 | 2.124 | 1.022 | 432 | 292 | 147 | -18 | -18 | -18 |
| Shareholders Funds | 5.028 | 3.936 | 10.070 | 14.348 | 18.661 | 18.120 | 17.550 | 17.371 | 15.852 | 15.763 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 1.571 | 707 | 358 | 16 | 97 | 13 | 13 | 13 | 13 | 13 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "7311 - 7311" | |||||||||
| CAEN Financial Year |
7312
|
|||||||||
Comments - Yrma Pharm Srl